A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age:18-75 years old
• Advanced endometrial cancer and platinum-resistant ovarian cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Expected survival \>=12 weeks.
• Signed informed consent form.
Locations
Other Locations
China
Chongqing Cancer Hospital
RECRUITING
Chongqing
Contact Information
Primary
ZHOU, PhD
qizhou9128@163.com
13708384529
Time Frame
Start Date: 2024-10-10
Estimated Completion Date: 2026-08
Participants
Target number of participants: 80
Treatments
Experimental: SSGJ-707(dose 1)+ carboplatin + paclitaxel
Experimental: SSGJ-707(dose 2)+ carboplatin + paclitaxel
Experimental: SSGJ-707(dose 3)+ carboplatin + paclitaxel
Experimental: SSGJ-707(dose 4)+ paclitaxel
Related Therapeutic Areas
Sponsors
Leads: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.